Neuren Pharmaceuticals (ASX:NEU) share price rockets 100% on study results

Why are investors so excited about Neuren Pharmaceuticals today?

| More on:
three excited doctors with hands in the air

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price is soaring to yearly highs on the back of positive phase three clinical trial results.

Shares are currently swapping hands at $3.40 apiece, up exactly 100% from yesterday’s close.

Let’s investigate what triggered the major boost for the drug therapy company today.

Why did Neuren announce?

Neuren reported positive results from phase three trials into the use of trofinetide to treat young women with Rett syndrome. Trofinetide has been granted fast-track status and orphan drug designation for Rett syndrome.

Acadia Pharmaceuticals (NASDAQ: ACAD) is conducting and funding the trials, but Neuren is eligible to receive milestone payments of up to US$455 million (AU$645 million). Neuren is also eligible for royalties on trofinetide sales if the drug is approved by the FDA.

Acadia is planning to meet with the FDA for a new drug application in the middle of 2022.

Neuren predicts it would earn AU$111 million in revenue over 2022 and 2023 for Rett syndrome, plus double-digit percentage royalties on net sales if trofinetide is approved and launched in the US.

Rett syndrome is a rare genetic mutation affecting brain development, primarily in girls.

What did management say?

Commenting on the news driving the Neuren Pharmaceuticals share price today, CEO Jon Pilcher said:

We are delighted with these robustly positive results and are now eager to see trofinetide progress through the regulatory approval process.

We are very grateful to the Rett syndrome community — the patients, their caregivers, study site personnel, physicians and everyone who participated in the Lavender study, as well as in Neuren’s two Phase 2 studies that paved the way.

Neuren Pharmaceuticals share price snapshot

The Neuren Pharmaceuticals share price has skyrocketed 164% this year to date. It has also gained 170% over the past 12 months.

Earlier today, the share price reached $3.56, a yearly high. The yearly low is $1.18.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A young woman slumped in her chair while looking at her laptop
Healthcare Shares

Mesoblast share price slides 8% following $65m capital injection

Mesoblast took a hit early in the session today.

Read more »

Medical technicians wearing white medical coats conduct a test in a laboratory.
Healthcare Shares

CSL share price climbs as $16 billion Vifor acquisition becomes effective

CSL shares are in the green on Tuesday...

Read more »

A man wearing a white coat holds his hands up and mouth open with joy.
Healthcare Shares

‘Excited about the pipeline’: Why Wilson says the CSL share price is in the buy zone right now

Could the CSL share price rise?

Read more »

A group of three scientists talking excitedly while working in a lab on a diabetes test developed by Proteomics International Laboratories which is an ASX share tipped to explode by Alto Capital
Healthcare Shares

Why is the Paradigm Biopharmaceuticals share price up 12% on Monday?

It's been a cracking start to the week for the ASX-listed drug repurposing company.

Read more »

A man sits in a chair hunched over a laptop and covered head to toe in frozen icicles to represent Envirosuite's trading halt
Healthcare Shares

Why is the Mesoblast share price still not moving today?

Mesoblast shares won't be going anywhere for the next few days.

Read more »

A person plunges into the pool with only their feet visible above the surface, diving through a heart-shaped inflatable ring.
Share Fallers

Here’s why the Medical Developments share price is sinking 17% on Monday

The share has caught sellers attention today.

Read more »

Happy healthcare workers in a labs
Healthcare Shares

Mayne Pharma share price lifts on FDA approval

It's a good start to the trading week for the ASX pharmaceutical company.

Read more »

A little boy surrounded by green grass and trees looks up at the sky, waiting for rain or sunshine.
Healthcare Shares

‘World’s largest portfolio’: Why this ASX cannabis share is up 36% in August

Investors have rewarded recent news.

Read more »